TDC
DNTH icon

Thompson Davis & Co’s Dianthus Therapeutics DNTH Stock Holding History

Thompson Davis & Co’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$4K Hold
20
– – 0.01% 598
2018
Q2 		$4K Buy
+20
New +$4.51K 0.01% 531

Other funds holding DNTH

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Thompson Davis & Co's DNTH Position: Q3 2018 in Review

Thompson Davis & Co held its Dianthus Therapeutics (DNTH) position steady in Q3 2018 at 20 shares worth $4K. The position accounts for 0.01% of the portfolio, ranked #598.

Thompson Davis & Co first reported a position in DNTH in Q2 2018 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold DNTH as of Q3 2018.

  • Thompson Davis & Co held 20 shares of Dianthus Therapeutics worth $4K as of Q3 2018.
  • Thompson Davis & Co left its Dianthus Therapeutics share count unchanged in Q3 2018.
  • Dianthus Therapeutics made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #598 holding.
  • Thompson Davis & Co first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.